期刊
JOURNAL OF BIOMEDICAL SCIENCE
卷 25, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s12929-018-0440-6
关键词
Epithelial-mesenchymal transition; Leukemia; Lymphoma
资金
- National Health Research Institutes [NHRI-EX107-10622BI]
- Taipei Veterans General Hospital [V107C-071]
- Ministry of Health and Welfare, Center of Excellence for Cancer Research [MOHW106-TDU-B-211-144-003]
Background: Epithelial-mesenchymal transition is an important process in embryonic development, fibrosis, and cancer metastasis. During the progression of epithelial cancer, activation of epithelial-mesenchymal transition is tightly associated with metastasis, stemness and drug resistance. However, the role of epithelial-mesenchymal transition in non-epithelial cancer is relatively unclear. ' Main body: Epithelial-mesenchymal transition transcription factors are critical in both myeloid and lymphoid development. Growing evidence indicates their roles in cancer cells to promote leukemia and lymphoma progression. The expression of epithelial-mesenchymal transition transcription factors can cause the differentiation of indolent type to the aggressive type of lymphoma. Their up-regulation confers cancer cells resistant to chemotherapy, tyrosine kinase inhibitors, and radiotherapy. Conversely, the down-regulation of epithelial-mesenchymal transition transcription factors, monoclonal antibodies, induce lymphoma cells apoptosis. Conclusions: Epithelial-mesenchymal transition transcription factors are potentially important prognostic or predictive factors and treatment targets for leukemia and lymphoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据